The size of the Middle East and Africa Diabetic Retinopathy Market was worth USD 0.7 Billion in 2020 and will reach USD 0.97 Billion by 2025, at a CAGR of 6.86% during the forecast period.
Diabetic retinopathy, the most common diabetic eye disease, occurs when blood vessels in the retina change. Sometimes these vessels close off entirely or even swell and leak fluid. In other cases, abnormal new blood vessels grow on the surface of the retina.
The remarkable rise in the incidence of diabetes in the Middle East and Africa makes the region the fastest developing geographical market during the forecast period. Increasing focus of market players to advance their foothold in the Middle East market, the rapid development of healthcare infrastructure, and growing government and non-government initiatives for emerging consciousness about diabetes management in the general population are a few of the other key factors driving the growth of the MEA diabetic retinopathy market. Other drivers of the diabetic retinopathy market in the Middle East and Africa markets are
The occurrence of an increase in diabetes in this MEA region is the fastest-growing during the period. Factors that cause the growth in the market are the increasing focus of market players, growing focus on the development of healthcare infrastructure, and also private and public initiatives to create awareness about diabetes management. The growing occurrence of diabetes, lack of diagnosis at the right time and even a non-compliant retinal screening of diabetic patients are likely to promote the demand of this market.
Companies like Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc. are playing a leading role in the MEA Diabetic Retinopathy Market.
This research report has been segmented and sub-segmented into the following categories:
By Treatment Type:
By Indication:
By End-User:
By Country:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug
5.1.2 Intraocular Steroid Injection
5.1.3 Laser Surgery
5.1.4 Vitrectomy
5.2 By Indication
5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)
5.2.1.1 Mild
5.2.1.2 Moderate
5.2.1.3 Severe
5.2.2 Proliferative Diabetic Retinopathy (PDR)
5.3 By End Users
5.3.1 Hospitals
5.3.2 Ophthalmic Clinics
5.3.3 Ambulatory Surgical Centers
6. Geographical Analysis
6.1 Introduction
6.2 Middle-East
6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bayer AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Hoffmann-La Roche ltd
8.4 Regeneron Pharmaceutical Inc.
8.5 Novartis AG
8.6 Valeant Pharmaceutical International Inc.
8.7 Abbott Laboratories Inc.
8.8 Alimera Science Inc.
8.9 Ampio Pharmaceuticals Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
